Ticker Scout
← tickerscout.ai

Altria Group, Inc. (MO)

CIK 0000764180 · NYSE · Latest period: Q2 FY2026 (ended 2026-06-30, 10-Q accession 0000764180-26-000094) · Annual report: FY2025 10-K (filed 2026-02-25, accession 0000764180-26-000017)

This record covers Q2 FY2026. Altria has since filed a 10-Q for the period ended 2026-09-30, on 2026-10-29 (SEC accession 0000764180-26-000114), which this page does not yet cover. Next expected filing: 10-K ~2027-02-24.

PeriodQ2 FY2026

Published

MetricAmountvs. year ago
Net revenues$6,111,000,000up 0.1%
Net earnings$2,298,000,000down 3.4%
Diluted EPS$1.37down 2.8%
Revenue net of excise taxes$5,356,000,000up 1.2%
Smokeable products revenue$5,392,000,000up 0.7%
Dividend declared per share$1.06up 3.9%

Company details

NameAltria Group, Inc.
TickerMO
CIK0000764180
ExchangeNYSE
StateVirginia
IncorporationVirginia
SIC2111
OfficeManufacturing
IndustryCigarettes
Latest period coveredQ2 FY2026, ended 2026-06-30, 10-Q, accession 0000764180-26-000094
Fiscal year end12/31 (MM/DD)

AI synthesis of five filings for Altria Group, Inc.

Business

From the FY2025 Annual Report on Form 10-K, accession 0000764180-26-000017.

Altria sells nicotine products to U.S. consumers age 21 and over, operating almost entirely inside the United States and generating substantially all of its revenue from domestic customers. Cigarettes are the overwhelming majority of the business: Philip Morris USA Inc. ("PM USA") is the largest cigarette company in the country, and Marlboro, its principal brand, has been the largest-selling cigarette brand in the United States for over 50 years. Products are sold principally to wholesalers, distributors and large retail organizations including chain stores. In the year ended December 31, 2025, net revenues of $23,279 million (including excise taxes billed to customers) broke down as $20,485 million from smokeable products, $2,802 million from oral tobacco products, and the balance negligible or negative in the e-vapor and all other lines.

The operating companies are organized by product form:

  • Smokeable products. PM USA manufactures and sells combustible cigarettes; John Middleton Co. ("Middleton"), a PM USA subsidiary, manufactures and sells machine-made large cigars under the Black & Mild brand, contracting with a third-party importer for substantially all of its cigars. Segment domestic cigarette shipment volume was 61.8 billion units in 2025, down 10.0% from 2024; cigar shipment volume was approximately 1.8 billion units, up 1.8%. Premium cigarettes were 93.6% of reported domestic cigarette shipment volume in 2025, down from 95.9% in 2024.
  • Oral tobacco products. U.S. Smokeless Tobacco Company LLC ("USSTC") is the leading producer and marketer of moist smokeless tobacco ("MST"), with premium brands Copenhagen and Skoal and value brand Red Seal; Helix Innovations LLC ("Helix") sells on! oral nicotine pouches. Segment shipment volume was 732.4 million cans in 2025, down 5.5%.
  • E-vapor products. NJOY, LLC sells e-vapor products supplied by third-party importers. Its portfolio of tobacco and menthol products is covered by FDA marketing granted orders ("MGO"), but its principal product, NJOY ACE, is subject to a U.S. International Trade Commission ("ITC") exclusion order and cease-and-desist orders barring importation and sale in the United States.

At December 31, 2025 the reportable segments were smokeable products, oral tobacco products and e-vapor products, with an all other category comprising Horizon Innovations LLC ("Horizon"), Helix International and other activities, chiefly research and development on new product platforms. Horizon is a joint venture in which Altria held a 75% economic interest at December 31, 2025, with JTI (US) Holding, Inc. ("JTIUH"), a subsidiary of Japan Tobacco Inc., holding 25%. Horizon is responsible for U.S. marketing and commercialization of heated tobacco stick ("HTS") products owned by either party; upon FDA authorization of Ploom HTS products, JTIUH would supply devices and PM USA would manufacture Marlboro HTS consumables. As of February 25, 2026 the joint venture had no products in the U.S. marketplace.

Support entities include Altria Group Distribution Company ("AGDC") for domestic sales and distribution and Altria Client Services LLC ("ALCS") for legal, regulatory, research and product development, consumer engagement, finance, human resources and external affairs. Altria also holds equity-method investments, reported on a one-quarter lag, in Anheuser-Busch InBev SA/NV ("ABI"), the world's largest brewer, and Cronos Group Inc. ("Cronos"), a Canadian cannabinoid company.

Raw material sourcing is split by company: PM USA buys the majority of its burley and flue-cured leaf directly from domestic growers under a contract growing program, with the remainder through leaf merchants; USSTC contracts similarly for dark fire-cured, dark air-cured and burley leaf; Middleton buys through leaf merchants with no growing program; Helix and NJOY purchase tobacco-derived nicotine materials from suppliers. The company describes the tobacco products market as highly competitive on brand recognition and loyalty, product quality, taste, price, innovation, marketing, packaging, distribution and promotion.

The stated strategy, "Moving Beyond Smoking", is to transition adult smokers to a smoke-free future, compete for existing smoke-free nicotine consumers, and pursue growth beyond the United States and beyond nicotine. Against that, management set 2028 Enterprise Goals: a mid-single-digit adjusted diluted EPS compound annual growth rate in 2028 from a recast $4.87 base in 2022; mid-single-digit annual dividend per share growth through 2028; a target debt-to-Consolidated EBITDA ratio of approximately 2.0x; maintaining U.S. tobacco leadership; maintaining total adjusted operating companies income ("OCI") margin of at least 60% in each year through 2028; competing internationally in top innovative oral tobacco markets while developing a path into heated tobacco and e-vapor; and entering non-nicotine categories with broad commercial distribution of at least five products by 2028. The U.S. smoke-free goals are explicitly under reassessment because of market disruption from illicit e-vapor products, with updated goals promised when the legitimate e-vapor market becomes clearer.

At December 31, 2025 Altria employed approximately 5,900 people, 26% of whom were hourly manufacturing employees covered by collective bargaining agreements. The Optimize & Accelerate initiative announced in October 2024 centralizes work, outsources certain transactional activities and standardizes processes enterprise-wide.

Risk factors

From the FY2025 Form 10-K, accession 0000764180-26-000017.

Volume decline and down-trading. The portfolio is concentrated in premium brands, Marlboro, Copenhagen, Skoal, whose buyers are sensitive to macroeconomic conditions. In periods of inflation and economic uncertainty, consumers reduce consumption, shift to discount brands and move to lower-priced nicotine products. If pricing cannot offset volume declines, results suffer. Evolving preferences, consumers moving across nicotine categories and buying illicit flavored e-vapor, have primarily driven domestic cigarette industry volume declines.

Illicit trade. Illicit flavored disposable e-vapor usage has increased sharply and such products now comprise the majority of the e-vapor category. This depresses FDA-authorized e-vapor volume and increases cross-category movement away from cigarettes. Altria states that enforcement actions to date have not materially curbed the proliferation, that it has increased engagement with the FDA and other agencies, and that it has taken its own legal action. Illicit trade also appears across nicotine pouches and cigarettes.

Competitive cost disadvantage from settlements. PM USA competes against lower-priced brands from manufacturers not party to settlements of healthcare cost recovery litigation and therefore not required to make the inflation-adjusted annual settlement payments that have driven substantial cigarette price increases. Additional price competition comes from diversion, counterfeiting and untaxed internet sales. A further risk is unequal access to "duty drawback" refunds of duties, taxes and fees on imported tobacco products.

Failure to commercialize innovative products. Growth depends on e-vapor, heated tobacco and oral nicotine pouches. The ITC bans on NJOY ACE importation and sale are under appeal to the U.S. Court of Appeals for the Federal Circuit but remain in effect during the appeal. JUUL Labs, Inc. ("JUUL") has filed similar patent infringement actions in the District of Arizona and with the ITC over NJOY Daily. FDA pre-market tobacco application ("PMTA") review periods are lengthy and unpredictable, and the FDA may bring enforcement against products commercialized while a PMTA has been pending beyond the statutory review period. Horizon's success depends on regulatory authorizations, commercialization milestones and consumer preferences, among other factors.

Impairment. In 2025 Altria recorded impairments of goodwill and other intangible assets in the e-vapor reporting unit as a result of the ITC orders and an expectation that effective enforcement against illicit flavored disposable e-vapor would occur more gradually than anticipated. Further non-cash impairments are possible if judgments about the e-vapor category or NJOY's business fail to materialize, if litigation goes badly, or if the discount rate rises. Separately, the Skoal trademark was impaired in the second quarter of 2024 as the MST category shrank under nicotine pouch growth, and a further Skoal impairment is possible.

Acquisitions and investments. Altria may be unable to realize the expected benefits of the NJOY Holdings, Inc. acquisition ("NJOY Transaction"). The filing notes the former investment in JUUL did not produce, and the investment in Cronos has not to date produced, the economic and competitive advantages expected.

Litigation. Proceedings pending or threatened in U.S. and foreign jurisdictions cover product liability, unfair trade practices, antitrust, tax, contraband, intellectual property, breach of contract, employment, environmental and RICO claims. Damages claimed have ranged into the billions, and non-monetary remedies are possible, in the Federal Government's RICO case the district court imposed no monetary penalties but ordered "corrective statements". The vast majority of tobacco cases historically have been filed in Florida, but filings against PM USA outside Florida have increased in recent years. Bonding relief may not be obtainable in all cases, though 47 states and Puerto Rico limit or waive bond amounts; the constitutionality of Florida's bond cap has been challenged.

Regulation. The Family Smoking Prevention and Tobacco Control Act ("FSPTCA") gives the FDA broad authority over advertising, pre-market review, product standards and enforcement. Altria cannot predict whether the FDA will authorize particular innovative products or impose a burdensome framework, nor whether it will enforce against violators, and it argues that FDA inaction creates competitive disadvantage by letting illicit products establish share while authorized products wait.

Excise taxes. Nicotine products carry substantial and rising excise taxes, pushing consumption down and shifting purchases toward discount, lower-taxed, counterfeit and contraband products. Substantial increases on e-vapor and oral nicotine products could also discourage smokers from switching.

Supply. Crop shifts, government price and production controls, trade sanctions, tariffs, labor disruption, inflation, geopolitical instability and climate events can raise cost or cut supply and quality of tobacco and other inputs (wood tips for cigars, aluminum for packaging are cited). Notably, the nicotine used in the innovative smoke-free products is extracted from tobacco produced in a single country. Altria also relies on a small number of manufacturing facilities and key suppliers and distributors. Single-use plastic bans and extended producer responsibility mandates could affect packaging.

Financing and ratings. Altria typically accesses the commercial paper market in the second quarter to help fund Master Settlement Agreement ("MSA") payments, tax obligations and dividends; credit market disruption or high rates would hurt liquidity and the dividend rate. A downgrade, as occurred following the JUUL investment, would raise borrowing costs and could impair commercial paper access.

Other. Risks also include recall exposure; public health emergencies; difficulty attracting and retaining skilled talent given declining social acceptance of tobacco; compliance with foreign laws including anti-bribery statutes; tax position challenges and rate changes; climate and sustainability regulation; investor responses to corporate responsibility performance (some investors will not hold tobacco companies at all); dependence on information technology largely managed by third-party providers, with artificial intelligence intensifying cyber risk; data protection and privacy compliance; currency translation, ABI business results, ABI share price and potential impairment on the ABI investment, plus reduced board nomination rights and possible loss of equity-method treatment if ownership falls below certain levels; and Cronos's exposure to cannabis laws including the U.S. Controlled Substances Act. Outsourcing under the Optimize & Accelerate initiative is itself flagged as raising risks to internal control, data protection and regulatory compliance.

Management's discussion, fiscal year 2025

From the FY2025 Form 10-K, accession 0000764180-26-000017.

Consolidated. Net revenues of $23,279 million decreased $739 million (3.1%), driven primarily by lower smokeable products revenue. Cost of sales fell $480 million (7.9%) on lower shipment volume and lower per unit settlement charges. Excise taxes on products fell $434 million (12.1%). Marketing, administration and research costs fell $230 million (8.4%), mainly lower acquisition-related items and the absence of 2024 transaction costs for the partial sale of the ABI investment (the "ABI Transaction"). Operating income fell $1,342 million (11.9%) to $9,899 million, principally on lower OCI, the 2025 e-vapor goodwill and definite-lived intangible impairments against the 2024 Skoal trademark impairment, partly offset by lower general corporate expenses.

Reported net earnings of $6,947 million fell $4,317 million (38.3%), driven mainly by the 2024 gain on the sale of the IQOS System commercialization rights and lower operating income; reported basic and diluted EPS of $4.12 each fell 37%. Adjusted net earnings of $9,148 million rose $212 million (2.4%) on higher OCI and a lower adjusted tax rate, partly offset by lower net periodic benefit income and higher net interest and other debt expense; adjusted diluted EPS of $5.42 rose 4.4%. (Income) losses from investments in equity securities were unfavorable by $142 million (21.8%), mainly lower ABI income including the prior-year gain on the ABI Transaction.

Special items in the year included: non-cash pre-tax impairment charges of $2,128 million to write the e-vapor reporting unit goodwill and definite-lived intangibles down to estimated fair value; pre-tax exit and implementation costs of $56 million for the Optimize & Accelerate initiative (2024: $68 million); pre-tax amortization of definite-lived intangibles of $132 million (2024: $139 million); a $25 million non-cash pre-tax charge for the change in fair value of NJOY contingent payments; and net pre-tax losses of $95 million on ABI-related special items, mostly mark-to-market losses on ABI financial instruments tied to its share commitments. Beginning in the first quarter of 2025 Altria began treating amortization of intangibles as a special item excluded from adjusted results, recasting prior periods. Across 2024 and 2025 combined, total costs of $151 million were incurred primarily in connection with the ITC orders and NJOY-related patent litigation, offset by $64 million of insurance recoveries. The Optimize & Accelerate initiative is expected to deliver cumulative savings of at least $600 million by the end of 2029, with estimated pre-tax charges revised up to approximately $175 million from approximately $125 million as all phases were finalized.

Trends. Through 2025 inflation stayed above the Federal Reserve's 2% target and discretionary income pressure was most acute among lower-income consumers. In the fourth quarter of 2025 the discount retail share of the cigarette category reached 32.9%, up 2.6 share points year over year and 0.7 sequentially. Adjusted for trade inventory movements and other factors, total domestic cigarette industry volume declined an estimated 6.5% in the fourth quarter versus 8% in the third quarter; management attributed the 1.5-point improvement primarily to illicit flavored disposable e-vapor growth moderating slightly. Altria also cut its estimate of cross-category movement's contribution to 2025 cigarette industry volume decline to roughly 2%–3% from a prior 3%–4%. The U.S. nicotine pouch category grew to 56.9% of the U.S. oral tobacco category in the fourth quarter, up 10.4 share points year over year. Flavored disposable e-vapor products, most of which Altria believes evaded the regulatory process, are estimated at approximately 70% of the e-vapor category. Management stated it did not observe a material impact on consumer purchasing behavior from tariffs and does not expect tariffs to materially affect 2026 costs on presently available information.

Smokeable products. Net revenues fell $719 million (3.4%) to $20,485 million as lower shipment volume ($2,426 million) outweighed higher pricing ($1,680 million, net of higher promotional investments). Reported OCI rose $163 million (1.5%) to $10,984 million and adjusted OCI rose $142 million (1.3%) to $11,064 million, on pricing and lower per unit settlement charges. Reported domestic cigarette shipment volume fell 10.0%, an estimated 9.5% adjusted for calendar differences, against an estimated 8% industry decline adjusted for calendar differences, trade inventory movements and other factors. Marlboro retail share of the premium segment was 59.4%, up 0.1 point; total industry discount category retail share was 31.8%, up 2.2 points. PM USA product liability defense costs were $113 million (2024: $125 million).

Oral tobacco products. Net revenues rose $26 million (0.9%) to $2,802 million as higher pricing ($263 million) was mostly offset by lower shipment volume and adverse volume/mix ($237 million). Reported OCI rose $379 million (26.2%) to $1,828 million, largely because of the prior year's $354 million Skoal trademark impairment; adjusted OCI rose $24 million (1.3%) to $1,835 million. Reported domestic shipment volume fell 5.5% (an estimated 4.5% adjusted for calendar differences and trade inventory movements). Segment retail share was 31.9%, down 5.4 points on MST declines. The U.S. nicotine pouch category reached 53.3% of the oral tobacco category, up 10.0 points, while on! share of the nicotine pouch category was 15.4%, down 3.4 points. Prior-period retail share and industry volume data were restated from the first quarter of 2025 to include synthetic oral nicotine pouch products.

E-vapor products. For 2025 the segment reported net revenues of $(13) million and reported OCI of $(2,297) million, which on an adjusted basis, excluding $2,128 million of impairments and $67 million of acquisition and disposition-related items, was $(102) million. Total company adjusted OCI was $12,568 million on an adjusted OCI margin of 62.4%.

Liquidity. Cash and cash equivalents were $4.5 billion at December 31, 2025, alongside commercial paper access and full availability of a $3.0 billion senior unsecured five-year revolving credit agreement. Total long-term debt was $25.7 billion (2024: $24.9 billion), all fixed rate, at a weighted-average coupon of approximately 4.5% (2024: 4.3%). During 2025 Altria issued $1.0 billion of senior unsecured notes in each of the first and third quarters ($2.0 billion total) and, in the second quarter, repaid at maturity $750 million of senior unsecured notes and €750 million ($857 million) of senior unsecured Euro notes. Net cash provided by operating activities was $9.3 billion (2024: $8.8 billion). Investing activities used $0.3 billion against $2.2 billion provided in 2024, which had included ABI Transaction proceeds. Capital expenditures rose 52.1% to $216 million. Financing activities used $7.6 billion (2024: $11.5 billion). Dividends paid were approximately $6,960 million, up 1.7%; in the third quarter of 2025 the Board raised the quarterly dividend 3.9% to $1.06 per share, an annualized rate of $4.24. In October 2025 the Board expanded the existing share repurchase program from $1.0 billion to $2.0 billion, expiring December 31, 2026. Payments under the State Settlement Agreements and FDA user fees were approximately $3.5 billion (2024: $3.9 billion), with $3.0 billion on average estimated as the annual charge to cost of sales for the next three years.

Current quarter, second quarter and first half of 2026

From the Form 10-Q for the quarter ended June 30, 2026, accession 0000764180-26-000094, and the earnings release furnished as Exhibit 99.1 to the Form 8-K filed July 30, 2026, accession 0000764180-26-000093.

Segment change. During the first quarter of 2026 Altria concluded that the e-vapor products operating segment was no longer expected to be of continuing significance and no longer met the quantitative thresholds of ASC 280. E-vapor was therefore removed as a reportable segment and folded back into the all other category for all periods presented. At June 30, 2026 the reportable segments were smokeable products and oral tobacco products; all other comprises e-vapor (NJOY), Horizon, Helix International and other business activities, principally research and development. This reverses the presentation used in the FY2025 Form 10-K, where the 2025 e-vapor impairments had pushed that operating segment over the reportable threshold.

Consolidated results. Second-quarter net revenues were essentially unchanged at $6,111 million (up 0.1%), as higher smokeable products and all other revenue offset lower oral tobacco revenue; revenues net of excise taxes rose 1.2% to $5,356 million. Operating income fell $94 million (2.9%) to $3,136 million on lower OCI and higher general corporate expenses. Reported net earnings of $2,298 million fell $80 million (3.4%) and reported basic and diluted EPS of $1.37 each fell 2.8%. Adjusted net earnings of $2,480 million rose $47 million (1.9%) and adjusted diluted EPS of $1.48 rose 2.8%. The reported effective tax rate was 21.5% (down 2.2 points) and the adjusted rate 23.0%.

For the six months, net revenues rose $178 million (1.6%) to $11,539 million and revenues net of excise taxes rose 3.1% to $10,114 million. Operating income rose $1,074 million (21.4%) to $6,092 million, largely because the prior-year period carried the e-vapor goodwill impairment. Reported net earnings of $4,481 million rose $1,026 million (29.7%) and reported diluted EPS of $2.67 rose 30.9%. Adjusted net earnings of $4,698 million rose $176 million (3.9%) and adjusted diluted EPS of $2.80 rose 4.9%. The six-month reported income tax rate was 22.6% against 28.0% a year earlier, the decline driven mainly by the prior year's non-deductible e-vapor goodwill impairment and by tax benefits from the effective settlement with the IRS in May 2026 of the 2017 tax year audit. That settlement excluded Altria's 2017 refund claim arising from the Tax Cuts and Jobs Act's removal of downward attribution rules relevant to the ABI investment; the claim was denied in September 2025 and Altria is pursuing appellate remedies.

USSTC Facilities Consolidation. In May 2026 Altria announced a plan to move USSTC's manufacturing operations from the Nashville, Tennessee plant to a new facility to be built on the existing Hopkinsville, Kentucky campus, expected to be substantially complete in the first quarter of 2028. Total pre-tax charges are estimated at approximately $180 million, cash employee separation and associated costs plus non-cash asset-related charges for inventory and machinery and equipment. Charges of $78 million were recorded in the second quarter ($59 million non-cash asset-related, $19 million employee separation), with no cash paid as of June 30, 2026. Separately, cumulative Optimize & Accelerate pre-tax charges since inception reached $140 million of an estimated $175 million total, with most of the remainder expected by the end of 2027.

Leadership transition. William F. Gifford, Jr. retired as Chief Executive Officer and as a director effective May 14, 2026, at the conclusion of the 2026 Annual Meeting of Shareholders, a succession announced in the Form 8-K filed December 11, 2025, accession 0000764180-25-000133. Salvatore Mancuso, previously Executive Vice President and Chief Financial Officer, became Chief Executive Officer and Heather A. Newman became Executive Vice President and Chief Financial Officer, both effective the same date. Mr. Gifford is providing transition consulting services through December 31, 2026 under a Consulting Agreement dated May 15, 2026, which appears in the exhibit index to the Form 10-Q for the quarter ended June 30, 2026 as item 10.3, alongside an Agreement and General Release of the same date as item 10.1.

Smokeable products. Second-quarter net revenues rose $35 million (0.7%) to $5,392 million as higher pricing ($309 million) outweighed adverse volume/cigarette mix ($279 million); revenues net of excise taxes rose 2.0% to $4,660 million. Reported OCI rose $12 million (0.4%) to $2,942 million, helped by pricing and $27 million of higher refunds of taxes and duties on imported cigarettes but held back by volume/cigarette mix ($221 million), higher tobacco and health and certain other litigation items ($63 million) and higher costs ($44 million). Adjusted OCI rose $71 million (2.4%) to $3,018 million, with adjusted OCI margin up 0.3 points to 64.8%; reported OCI margin fell 1.0 point to 63.1%. Reported domestic cigarette shipment volume fell 3.2% to 15,554 million sticks, an estimated 4.5% adjusted for trade inventory movements, against an estimated 5% industry decline. Marlboro volume fell 7.4% while discount volume rose 67.3%; cigar shipment volume rose 5.0%. Contract manufactured export cigarettes rose 54.9% to 736 million sticks. Marlboro retail share of the total cigarette category was 39.5%, down 1.5 points year over year, though its share of the premium segment held at 59.6%. Industry discount retail share was 33.8%, up 2.6 points. For the six months, net revenues rose $171 million (1.7%) and both reported and adjusted OCI rose, by $216 million (4.0%) and $229 million (4.2%) respectively, with adjusted OCI margin up 0.4 points to 64.9%.

Oral tobacco products. Second-quarter net revenues fell $40 million (5.3%) to $713 million on lower shipment volume ($74 million) partly offset by higher pricing ($31 million). Reported OCI fell $117 million (23.5%) to $381 million, driven by the $78 million of USSTC Facilities Consolidation costs and lower volume; adjusted OCI fell $40 million (8.0%) to $460 million and adjusted OCI margin fell 2.0 points to 66.7%, while reported OCI margin fell 13.2 points to 55.2%. Reported domestic shipment volume fell 8.5% to 181.7 million cans, an estimated 2% decline adjusted for trade inventory movements. Copenhagen shipments fell 10.9% and Skoal 13.7%, while on! fell 4.2%. Segment retail share was 29.0%, down 3.7 points year over year and unchanged sequentially. The nicotine pouch category reached 59.9% of the oral tobacco category, up 8.1 points year over year and 1.8 sequentially; on! share of the nicotine pouch category was 14.4%, down 1.7 points year over year but up 1.0 point sequentially, and on! share of the total oral tobacco category was 8.6%, up 0.3 points. For the six months, net revenues fell $25 million (1.8%), reported OCI fell $115 million (12.4%) and adjusted OCI fell $39 million (4.2%).

Smoke-free portfolio. Helix expanded on! PLUS to 120,000 stores nationwide, resumed shipments of 12-milligram on! PLUS in Florida, North Carolina and Texas in Mint, Wintergreen and Tobacco with national expansion planned for the third quarter, and plans additional flavors across 6-, 9- and 12-milligram strengths beginning with Blueberry Mint and Mango Pineapple in the fourth quarter. The FDA issued MGOs in December 2025 for on! PLUS in tobacco, mint and wintergreen at 6 mg and 9 mg; as of July 27, 2026 no further marketing order had been issued for other on! PLUS products. Helix filed additional on! PLUS PMTAs in November 2025 and June 2026. In May 2026 the FDA issued guidance that it generally will not prioritize enforcement against e-vapor and oral nicotine pouch products with pending PMTAs undergoing scientific review, or pending supplemental PMTAs (other than flavored e-vapor) accepted and pending more than 180 days, while reserving case-by-case enforcement. Horizon still had no products in the U.S. marketplace at June 30, 2026.

Trends. Through the second quarter of 2026, inflationary pressure on discretionary income continued, most acutely among lower-income consumers; gas prices averaged $4.05 per gallon during June amid Middle East-driven energy volatility, and June inflation ran at 3.5%. Management believes the moderating domestic cigarette industry volume decline that began in the third quarter of 2025 continues to be driven primarily by reduced cross-category movement between cigarettes and illicit flavored disposable e-vapor products.

Balance sheet and capital returns. Cash and cash equivalents were $2,367 million at June 30, 2026 against $4,474 million at December 31, 2025. Total long-term debt was $24.6 billion, down from $25.7 billion, after repaying approximately $1.1 billion of 4.400% senior unsecured notes at maturity in February 2026; there were no short-term borrowings and the $3.0 billion credit agreement, which expires October 24, 2029, was fully available. Short- and long-term credit ratings carried stable outlooks from Moody's, S&P (BBB+) and Fitch (BBB+). Net cash provided by operating activities for the first half was $3,043 million (2025: $2,925 million); investing used $166 million (2025: $79 million); financing used $4,988 million (2025: $4,693 million). Dividends paid in the first half were $3,556 million, up 3.0%, at an annualized rate of $4.24 per share. Altria repurchased 0.8 million shares in the quarter at an average $65.11 for $55 million, and 5.3 million shares in the half at an average $62.78 for $335 million, leaving $665 million under the $2.0 billion program expiring December 31, 2026. Payments under the State Settlement Agreements and FDA user fees were approximately $2.6 billion in the first half (2025: $2.9 billion).

Investments. At June 30, 2026 Altria held an approximate 8.1% interest in ABI (approximately 125 million restricted shares and 34 million ordinary shares) carried at $8,577 million against a fair value of $13.2 billion, a 54% excess over carrying value versus 24% at December 31, 2025. The Cronos stake was approximately 42.2% (about 157 million shares), carried at $319 million against $432 million fair value. ABI-related special items were net pre-tax losses of $77 million in the quarter and $78 million in the half, driven by a $114 million pre-tax dilution loss from ABI share activity that reduced Altria's ownership interest, partly offset by mark-to-market gains.

Impairment testing. No events or circumstances indicated an interim quantitative impairment assessment was required as of June 30, 2026. E-vapor reporting unit goodwill remained $610 million. Based on the 2025 annual test, a hypothetical one-point increase in the discount rate would have produced an approximately $150 million e-vapor goodwill impairment; the Skoal trademark's fair value exceeded carrying value by approximately 7% ($0.3 billion) at December 31, 2025, and a one-point discount rate increase would have implied an approximately $90 million charge.

Litigation. As of July 27, 2026 there were 247 individual smoking and health cases pending against Altria in the United States (195 a year earlier), 24 e-vapor cases, three other tobacco-related cases and no health care cost recovery actions. Approximately 43 state court Engle progeny cases were pending. Of 148 federal and state Engle progeny cases that have gone to verdict involving PM USA, 88 were returned for plaintiffs (four since reversed and still pending) and 60 for PM USA. Since October 2004 PM USA has paid judgments and settlements totaling approximately $1.2 billion plus approximately $245 million of interest, including approximately $454 million of Engle progeny judgments and $62 million of related interest. The accrued liability for tobacco and health and certain other litigation items rose to $156 million at June 30, 2026 from $71 million at the start of the year. In October 2025 a Minnesota court found PM USA owes the State of Minnesota $10 million plus interest in a State Settlement Agreement enforcement action; PM USA has appealed. NJOY's September 2025 ITC action against JUUL has an ALJ hearing scheduled for September 2026, with an initial determination expected in December 2026 and an ITC final determination expected in April 2027.

Guidance. Altria narrowed its 2026 full-year adjusted diluted EPS guidance to a range of $5.61 to $5.72, a growth rate of 3.5% to 5.5% from the $5.42 base in 2025, raising the lower end of the prior range. The guidance contemplates moderated e-vapor industry growth affecting combustible and e-vapor volumes; increased macroeconomic uncertainty for adult nicotine consumers; investments supporting contract manufacturing capabilities; NJOY ACE not returning to the marketplace in 2026; reinvestment of anticipated Optimize & Accelerate savings; and investments supporting the Vision. Management expects a greater benefit from cigarette import and export activity in the second half than the first, more evenly balanced between the third and fourth quarters than previously expected. Capital expenditures for 2026 are now expected at $375 million to $450 million, up from $300 million to $375 million, primarily reflecting the USSTC Facilities Consolidation.

Subsequent events

Altria's Form 10-Q for the quarter ended June 30, 2026 (accession 0000764180-26-000094) contains no separate subsequent events note; material post-period developments are disclosed within the individual notes and the pricing-action tables, and in Current Reports on Form 8-K filed after the quarter end. Those developments are:

  • Pricing action (July 19, 2026). Effective July 19, 2026, PM USA increased the list price of Marlboro (excluding Mainline Menthol and 72s Menthol) and L&M by $0.17 per pack, and increased the list price of all its other premium cigarette brands by $0.22 per pack. (Form 10-Q, accession 0000764180-26-000094.)
  • Canadian class certification (July 2026). The court in a British Columbia e-vapor class action certified a nationwide class of Canadian residents who used and directly or indirectly purchased JUUL e-vapor products for primarily personal purposes starting in August 2018. The class seeks compensatory and punitive damages, including for personal injuries allegedly suffered from using JUUL e-vapor products. Altria intends to appeal the class certification order. Altria is named as a defendant in four e-vapor class actions in Canada. (Form 10-Q, accession 0000764180-26-000094.)
  • JUUL-related settlement payment (July 2026). In the second quarter of 2026 Altria recorded an additional pre-tax provision of $4 million relating to the previously agreed settlement with Native American tribes in the JUUL e-vapor litigation and paid that amount in July 2026. (Form 10-Q, accession 0000764180-26-000094.)
  • Second-quarter results and narrowed guidance (July 30, 2026). Altria issued its second-quarter and first-half 2026 earnings release and narrowed full-year 2026 adjusted diluted EPS guidance to $5.61–$5.72, raising the lower end of the range. (Form 8-K, accession 0000764180-26-000093, Exhibit 99.1.)
  • Board expansion and director election (August 27–28, 2026). The Board increased its size from 10 to 11 directors and elected Steven W. Presley as a director, both effective August 27, 2026, announced by press release on August 28, 2026. Mr. Presley is Chief Executive Officer of Refresco Benelux B.V. and previously held senior roles at Nestlé S.A., including Executive Vice President and Chief Executive Officer Zone Americas. He joins the Compensation and Talent Development, Innovation and Finance Committees. (Form 8-K, accession 0000764180-26-000098, and Exhibit 99.1 thereto.)

No acquisitions, divestitures, financings or new borrowings were disclosed as occurring after June 30, 2026 in these filings.

AI synthesis of events in 14 filings

Filings that contain financial statements

  • 8-K dated January 29, 2026 (accession 0000764180-26-000009) furnishes Altria's full-year financial statements: the consolidated balance sheets as of December 31, 2025 and 2024, and the consolidated statements of earnings, comprehensive earnings, stockholders' equity (deficit) and cash flows for each of the three years ended December 31, 2025, together with the independent registered public accounting firm's report (Exhibit 99.2) and management's report on internal control over financial reporting (Exhibit 99.3). These statements were also included in Altria's Annual Report on Form 10-K for the year ended December 31, 2025.
  • 8-K dated January 29, 2026 (accession 0000764180-26-000007), Exhibit 99.1, carries the 2025 fourth-quarter and full-year earnings press release, including the consolidated statements of earnings, selected segment data, and a condensed consolidated balance sheet as of December 31, 2025.
  • 8-K dated April 30, 2026 (accession 0000764180-26-000056), Exhibit 99.1, carries the first-quarter 2026 results, including the consolidated statement of earnings and condensed consolidated balance sheet as of March 31, 2026.
  • 8-K dated July 30, 2026 (accession 0000764180-26-000093), Exhibit 99.1, carries the second-quarter and first-half 2026 results, including the consolidated statements of earnings for the quarter and six months ended June 30, 2026, and the condensed consolidated balance sheet as of June 30, 2026.
  • 8-K dated October 30, 2025 (accession 0000764180-25-000128), Exhibit 99.1, carries the third-quarter 2025 results.
  • 8-K dated July 30, 2025 (accession 0000764180-25-000109), Exhibit 99.1, carries the second-quarter and first-half 2025 results.
  • 8-K dated April 29, 2025 (accession 0000764180-25-000047), Exhibit 99.1, carries the first-quarter 2025 results.

Earnings and Guidance

Second-quarter and first-half 2026 (reported July 30, 2026; accession 0000764180-26-000093). Net revenues were $6.1 billion in the quarter (up 0.1%) and $11.5 billion for the first half (up 1.6%). Reported diluted EPS was $1.37 for the quarter (down 2.8%) and $2.67 for the first half (up 30.9%, which included a 2025 non-cash e-vapor goodwill impairment in the prior-year base). Adjusted diluted EPS was $1.48 for the quarter (up 2.8%) and $2.80 for the first half (up 4.9%). Altria narrowed its full-year 2026 adjusted diluted EPS guidance to $5.61–$5.72 (from a prior range of $5.56–$5.72), representing growth of 3.5%–5.5% from a $5.42 base in 2025, raising the low end of the range. The company also raised its 2026 capital expenditure outlook to $375–$450 million (from $300–$375 million), reflecting investment to consolidate U.S. Smokeless Tobacco Company's manufacturing operations.

First-quarter 2026 (reported April 30, 2026; accession 0000764180-26-000056). Net revenues were $5.4 billion (up 3.2%). Reported diluted EPS was $1.30 (up from $0.63, which had included a 2025 e-vapor goodwill impairment); adjusted diluted EPS was $1.32 (up 7.3%). Altria reaffirmed full-year 2026 adjusted diluted EPS guidance of $5.56–$5.72.

Fourth-quarter and full-year 2025 (reported January 29, 2026; accession 0000764180-26-000007). Fourth-quarter net revenues were $5.8 billion (down 2.1%); full-year net revenues were $23.3 billion (down 3.1%). Fourth-quarter reported diluted EPS was $0.66 (down 63.1%), reflecting non-cash impairments of e-vapor reporting-unit goodwill and related intangible assets. Full-year reported diluted EPS was $4.12 (down 37.0% from a 2024 base that included a $2.7 billion gain on the IQOS commercialization-rights assignment). Full-year adjusted diluted EPS was $5.42 (up 4.4%). Altria issued initial full-year 2026 adjusted diluted EPS guidance of $5.56–$5.72.

Third-quarter 2025 (reported October 30, 2025; accession 0000764180-25-000128), second-quarter 2025 (reported July 30, 2025; accession 0000764180-25-000109), and first-quarter 2025 (reported April 29, 2025; accession 0000764180-25-000047) earnings releases are also on file; see the accessions above for the underlying statements.

Capital Returns and Capital Actions

  • Share repurchase program expanded (October 29, 2025; accession 0000764180-25-000128). Altria's Board authorized expanding the existing share repurchase program from $1 billion to $2 billion, with the expanded program expiring December 31, 2026.
  • Debt issuance (August 6, 2025; accession 0001193125-25-174546). Altria issued $500 million of 4.500% Notes due 2030 and $500 million of 5.250% Notes due 2035 (an aggregate $1 billion), each guaranteed by Philip Morris USA Inc., under its existing 2008 indenture.
  • Credit facility extended (July 23, 2025; accession 0000764180-25-000101). Altria extended the expiration date of its $3.0 billion senior unsecured five-year revolving credit agreement from October 24, 2028 to October 24, 2029; all other terms were unchanged.
  • Through the first half of 2026, Altria returned nearly $3.9 billion to shareholders via dividends and share buybacks combined, per the July 30, 2026 earnings release; for full-year 2025 the company returned $8 billion to shareholders via dividends and buybacks combined, per the January 29, 2026 release, including a dividend increase of 3.9% (the company's 60th increase in 56 years).

Leadership Transition

  • CEO and CFO succession announced (December 8–11, 2025; accession 0000764180-25-000133). William F. Gifford, Jr. notified the Board of his decision to retire as CEO and as a director effective at the conclusion of Altria's 2026 Annual Meeting (May 14, 2026), after more than 30 years with the company, including over five years as CEO. The Board elected Salvatore Mancuso (then EVP and CFO) to become CEO and Heather A. Newman (then SVP, Chief Strategy & Growth Officer) to become EVP and CFO, both effective at the conclusion of the 2026 Annual Meeting.
  • Mancuso elected to the Board (January 28–29, 2026; accession 0000764180-26-000007). Ahead of his CEO transition, the Board increased its size from 11 to 12 directors and elected Salvatore Mancuso, effective January 29, 2026.
  • 2026 Annual Meeting (held May 14, 2026) and related compensation actions (accession 0000764180-26-000073). Shareholders elected all 10 director nominees, ratified PricewaterhouseCoopers LLP as auditor for fiscal 2026, and approved, on an advisory basis, the company's executive compensation. In connection with the leadership transition, the Compensation Committee set Mancuso's base salary at $1,350,000 and Newman's at $800,000, both effective May 14, 2026, along with associated equity awards. Gifford's retirement included incentive-plan payouts pro-rated through his retirement date and a Consulting Agreement, dated May 15, 2026, under which he will provide consulting services through December 31, 2026 at $250,000 per month to support the CEO/CFO transition.
  • Board addition (August 27–28, 2026; accession 0000764180-26-000098). The Board increased its size from 10 to 11 directors and elected Steven W. Presley, Chief Executive Officer of Refresco Benelux B.V. and a former Nestlé S.A. zone CEO, as an independent director, effective August 27, 2026, assigning him to the Compensation and Talent Development, Innovation and Finance Committees.
  • Other board/management changes. George Muñoz, a director since 2004, announced on October 3, 2025 that he would retire from the Board at the end of his current term and not stand for re-election at the 2026 Annual Meeting (accession 0000764180-25-000124). Separately, Steven D'Ambrosia announced his retirement as Vice President and Controller effective July 31, 2025, and the Board elected Katie F. Patterson as his successor, effective upon his retirement (accession 0000764180-25-000057, filed in connection with the 2025 Annual Meeting held May 15, 2025, at which shareholders also ratified PricewaterhouseCoopers LLP as auditor, approved advisory say-on-pay, and approved the 2025 Performance Incentive Plan and the 2025 Stock Compensation Plan for Non-Employee Directors).

Smoke-Free Portfolio and Operational Notes

  • Helix (the company's oral-nicotine-pouch subsidiary) expanded on!PLUS distribution to 120,000 stores nationwide by the second quarter of 2026 and resumed shipments of 12-milligram on!PLUS in select states, with a national expansion planned for the third quarter of 2026 and additional flavor line extensions planned for the fourth quarter.
  • In December 2025, Helix received FDA marketing authorizations for on!PLUS products in mint, wintergreen and tobacco at 6- and 9-milligram nicotine strengths; the 12-milligram variants remained under FDA review at that time.
  • In August 2025, Horizon Innovations LLC, Altria's majority-owned joint venture for the U.S. marketing and commercialization of heated tobacco stick products, submitted a combined premarket tobacco product application and modified risk tobacco product application to the FDA for Ploom and Marlboro heated tobacco sticks, per the third-quarter 2025 earnings release (accession 0000764180-25-000128).
  • As of the second-quarter 2026 release, Altria's guidance continues to assume that NJOY ACE does not return to the marketplace in 2026, following the U.S. International Trade Commission's exclusion and cease-and-desist orders affecting that product. For full-year 2025, Altria recorded net pre-tax acquisition and disposition-related expense items of $76 million, including $51 million related to those ITC orders (accession 0000764180-26-000007).

No merger, acquisition or divestiture was signed or completed by Altria during the period covered by these filings.

Financials

Figures link to the filing they came from. Wherever the SEC filing tags a number, that number is linked: click it and the filing opens at the exact line that prints it. A figure with no link was either derived by AI, such as a margin, free cash flow or a trailing-twelve-month total, or taken from a filing that does not tag its numbers, such as an earnings release.

About this file

TickerMO
CIK0000764180
CompanyAltria Group, Inc.
Business typeconsumer staples (tobacco and nicotine products)
Schema templatestandard consumer-products: revenue, cost of sales, gross profit, operating income, net earnings, EPS; cash, debt, assets, equity; operating cash flow, capital expenditures, free cash flow, dividends, extended with the excise-tax line and the segment operating companies income measure Altria manages the business on
Reporting currencyUSD
Converted to USDno
Unitsactual dollars (not millions); share counts in actual shares; per-share amounts in dollars per share

MO annual income statement, balance sheet and cash flow

Taken from the SEC filings and normalized to actual dollars.

FY2025FY2024FY2023
Period start2025-01-012024-01-012023-01-01
Period end2025-12-312024-12-312023-12-31
Period typefiscal yearfiscal yearfiscal year
Source accession10-K10-K10-K
Income statement
Net revenues23,279,000,00024,018,000,00024,483,000,000
Cost of sales5,597,000,0006,077,000,0006,218,000,000
Excise taxes on products3,140,000,0003,574,000,0003,981,000,000
Gross profit14,542,000,00014,367,000,00014,284,000,000
Marketing administration and research costs2,507,000,0002,737,000,0002,737,000,000
Asset impairment and exit costs978,000,000389,000,0000
Impairment of goodwill1,158,000,00000
Operating income9,899,000,00011,241,000,00011,547,000,000
Interest and other debt expense net1,079,000,0001,037,000,000989,000,000
Net periodic benefit income excluding service cost-59,000,000-102,000,000-127,000,000
Income losses from investments in equity securities-510,000,000-652,000,000-243,000,000
Gain on sale of iqos system commercialization rights0-2,700,000,0000
Earnings before income taxes9,389,000,00013,658,000,00010,928,000,000
Provision for income taxes2,442,000,0002,394,000,0002,798,000,000
Net earnings6,947,000,00011,264,000,0008,130,000,000
Diluted EPS4.126.544.57
Earnings for basic and diluted EPS6,927,000,00011,236,000,0008,113,000,000
Diluted shares1,683,000,0001,718,000,0001,777,000,000
Revenues net of excise taxes20,139,000,00020,444,000,00020,502,000,000
Dividends declared per share4.164.003.84
Cash flow
Depreciation and amortization266,000,000286,000,000272,000,000
Net cash provided by used in operating activities9,290,000,0008,753,000,0009,287,000,000
Capital expenditures-216,000,000-142,000,000-196,000,000
Net cash provided by used in investing activities-341,000,0002,175,000,000-1,283,000,000
Long term debt issued1,992,000,0000998,000,000
Long term debt repaid-1,607,000,000-1,121,000,000-1,566,000,000
Repurchases of common stock-1,000,000,000-3,400,000,000-1,000,000,000
Dividends paid on common stock-6,960,000,000-6,845,000,000-6,779,000,000
Net cash provided by used in financing activities-7,615,000,000-11,491,000,000-8,374,000,000
Free cash flow9,074,000,0008,611,000,0009,091,000,000
Balance sheet
Cash and cash equivalents4,474,000,0003,127,000,000
Total current assets5,932,000,0004,513,000,000
Goodwill5,787,000,0006,945,000,000
Other intangible assets net11,876,000,00012,973,000,000
Investments in equity securities8,617,000,0008,195,000,000
Total assets35,017,000,00035,177,000,000
Current portion of long term debt1,569,000,0001,527,000,000
Total current liabilities9,154,000,0008,781,000,000
Long term debt24,140,000,00023,399,000,000
Total liabilities38,469,000,00037,365,000,000
Total stockholders equity attributable to altria-3,502,000,000-2,238,000,000
Noncontrolling interest50,000,00050,000,000
Total stockholders equity-3,452,000,000-2,188,000,000
Total debt25,709,000,00024,926,000,000
Shares outstanding at period end1,674,318,2971,690,651,867
Segment results
Net revenues
Smokeable products20,485,000,00021,204,000,00021,756,000,000
Oral tobacco products2,802,000,0002,776,000,0002,667,000,000
E vapor products-13,000,00040,000,00062,000,000
All other5,000,000-2,000,000-2,000,000
Operating companies income
Smokeable products10,984,000,00010,821,000,00010,670,000,000
Oral tobacco products1,828,000,0001,449,000,0001,722,000,000
E vapor products-2,297,000,000-171,000,000-16,000,000
All other-229,000,000-243,000,000-58,000,000
Amortization of intangibles-132,000,000-139,000,000-128,000,000
General corporate expenses-255,000,000-476,000,000-643,000,000

MO quarterly income statement, balance sheet and cash flow

Taken from the SEC filings and normalized to actual dollars.

Q2 2026Q2 2025
Period start2026-04-012025-04-01
Period end2026-06-302025-06-30
Period typethree monthsthree months
Source accession10-Q10-Q
Income statement
Net revenues6,111,000,0006,102,000,000
Cost of sales1,536,000,0001,440,000,000
Excise taxes on products755,000,000812,000,000
Gross profit3,820,000,0003,850,000,000
Marketing administration and research costs663,000,000619,000,000
Asset impairment and exit costs21,000,0001,000,000
Impairment of goodwill00
Operating income3,136,000,0003,230,000,000
Interest and other debt expense net295,000,000275,000,000
Net periodic benefit income excluding service cost-1,000,000-15,000,000
Income losses from investments in equity securities-87,000,000-148,000,000
Earnings before income taxes2,929,000,0003,118,000,000
Provision for income taxes631,000,000740,000,000
Net earnings2,298,000,0002,378,000,000
Diluted EPS1.371.41
Earnings for basic and diluted EPS2,292,000,0002,371,000,000
Diluted shares1,670,000,0001,684,000,000
Revenues net of excise taxes5,356,000,0005,290,000,000
Dividends declared per share1.061.02
Balance sheet
Cash and cash equivalents2,367,000,000
Total current assets4,022,000,000
Goodwill5,787,000,000
Other intangible assets net11,850,000,000
Investments in equity securities8,896,000,000
Total assets33,374,000,000
Current portion of long term debt1,684,000,000
Total current liabilities7,770,000,000
Long term debt22,893,000,000
Total liabilities35,992,000,000
Total stockholders equity attributable to altria-2,668,000,000
Noncontrolling interest50,000,000
Total stockholders equity-2,618,000,000
Total debt24,577,000,000
Shares outstanding at period end1,669,743,926
Segment results
Net revenues
Smokeable products5,392,000,0005,357,000,000
Oral tobacco products713,000,000753,000,000
All other6,000,000-8,000,000
Operating companies income
Smokeable products2,942,000,0002,930,000,000
Oral tobacco products381,000,000498,000,000
All other-77,000,000-108,000,000
Amortization of intangibles-23,000,000-37,000,000
General corporate expenses-87,000,000-53,000,000

MO year-to-date income statement and cash flow

Taken from the SEC filings and normalized to actual dollars.

Six months ended June 30, 2026
Period start2026-01-01
Period end2026-06-30
Period typesix months
Source accession10-Q
Income statement
Net revenues11,539,000,000
Excise taxes on products1,425,000,000
Revenues net of excise taxes10,114,000,000
Cost of sales2,788,000,000
Gross profit7,326,000,000
Marketing administration and research costs1,213,000,000
Asset impairment and exit costs21,000,000
Impairment of goodwill0
Operating income6,092,000,000
Interest and other debt expense net553,000,000
Net periodic benefit income excluding service cost-4,000,000
Income losses from investments in equity securities-245,000,000
Earnings before income taxes5,788,000,000
Provision for income taxes1,307,000,000
Net earnings4,481,000,000
Earnings for basic and diluted EPS4,470,000,000
Diluted EPS2.67
Diluted shares1,672,000,000
Dividends declared per share2.12
Cash flow
Depreciation and amortization112,000,000
Net cash provided by used in operating activities3,043,000,000
Capital expenditures-150,000,000
Free cash flow2,893,000,000
Net cash provided by used in investing activities-166,000,000
Net cash provided by used in financing activities-4,988,000,000
Long term debt issued0
Long term debt repaid-1,069,000,000
Repurchases of common stock-335,000,000
Dividends paid on common stock-3,556,000,000
Segment results
Net revenues
Smokeable products10,150,000,000
Oral tobacco products1,382,000,000
All other7,000,000
Operating companies income
Smokeable products5,615,000,000
Oral tobacco products816,000,000
All other-153,000,000
Amortization of intangibles-46,000,000
General corporate expenses-140,000,000

MO trailing twelve month income statement and cash flow

Derived by AI from the figures the filings report. No filing prints these, so none of them is linked.

Trailing twelve months ended June 30, 2026
Period start2025-07-01
Period end2026-06-30
Period typetrailing twelve months
Source accession10-K, 10-Q
Income statement
Net revenues23,457,000,000
Excise taxes on products3,013,000,000
Revenues net of excise taxes20,444,000,000
Cost of sales5,675,000,000
Gross profit14,769,000,000
Marketing administration and research costs2,513,000,000
Asset impairment and exit costs998,000,000
Impairment of goodwill285,000,000
Operating income10,973,000,000
Interest and other debt expense net1,095,000,000
Net periodic benefit income excluding service cost-34,000,000
Income losses from investments in equity securities-464,000,000
Earnings before income taxes10,376,000,000
Provision for income taxes2,403,000,000
Net earnings7,973,000,000
Earnings for basic and diluted EPS7,952,000,000
Diluted EPS4.75
Diluted shares1,668,000,000
Dividends declared per share4.24
Cash flow
Depreciation and amortization236,000,000
Net cash provided by used in operating activities9,408,000,000
Capital expenditures-296,000,000
Free cash flow9,112,000,000
Net cash provided by used in investing activities-428,000,000
Net cash provided by used in financing activities-7,910,000,000
Long term debt issued995,000,000
Long term debt repaid-1,069,000,000
Repurchases of common stock-735,000,000
Dividends paid on common stock-7,062,000,000
  • Derivation. Derived by adding the six months ended June 30, 2026 to the year ended December 31, 2025 and subtracting the six months ended June 30, 2025.

Adjustments

Splits appliednone
ADR ration/a
FXNone. Altria reports in U.S. dollars and no translation was required.

Prior year to date

Taken from the SEC filings and normalized to actual dollars.

Six months ended June 30, 2025
Period start2025-01-01
Period end2025-06-30
Period typesix months
Source accession10-Q
Income statement
Net revenues11,361,000,000
Excise taxes on products1,552,000,000
Revenues net of excise taxes9,809,000,000
Cost of sales2,710,000,000
Gross profit7,099,000,000
Marketing administration and research costs1,207,000,000
Asset impairment and exit costs1,000,000
Impairment of goodwill873,000,000
Operating income5,018,000,000
Interest and other debt expense net537,000,000
Net periodic benefit income excluding service cost-29,000,000
Income losses from investments in equity securities-291,000,000
Earnings before income taxes4,801,000,000
Provision for income taxes1,346,000,000
Net earnings3,455,000,000
Earnings for basic and diluted EPS3,445,000,000
Diluted EPS2.04
Diluted shares1,687,000,000
Dividends declared per share2.04
Cash flow
Depreciation and amortization142,000,000
Net cash provided by used in operating activities2,925,000,000
Capital expenditures-70,000,000
Free cash flow2,855,000,000
Net cash provided by used in investing activities-79,000,000
Net cash provided by used in financing activities-4,693,000,000
Long term debt issued997,000,000
Long term debt repaid-1,607,000,000
Repurchases of common stock-600,000,000
Dividends paid on common stock-3,454,000,000
Segment results
Net revenues
Smokeable products9,979,000,000
Oral tobacco products1,407,000,000
All other-25,000,000
Operating companies income
Smokeable products5,399,000,000
Oral tobacco products931,000,000
All other-1,122,000,000
Amortization of intangibles-74,000,000
General corporate expenses-116,000,000

Notes

  • Two filings are the source of everything here: Altria's annual report on Form 10-K for the year ended December 31, 2025 (accession 0000764180-26-000017) and its quarterly report on Form 10-Q for the quarter ended June 30, 2026 (accession 0000764180-26-000094). The 10-K's statements of earnings and cash flows print three years (2025, 2024 and 2023) and its balance sheets print two (December 31, 2025 and 2024); the 10-Q prints the second quarter and first half of 2026 against the same periods of 2025, a balance sheet at June 30, 2026, and cash flows for the six months only. Those are exactly the periods carried here.
  • Altria's statement of earnings deducts two lines from net revenues before gross profit: cost of sales and excise taxes on products. Net revenues are therefore stated gross of excise taxes. The line 'revenues net of excise taxes' is not printed on the face of the statement; it is net revenues less excise taxes on products, and it is the revenue base Altria discusses in its own management commentary.
  • Gross profit is net revenues less excise taxes on products less cost of sales; the deduction runs through three lines rather than the usual two.
  • The line named 'asset_impairment_and_exit_costs' is the same position on the statement in both filings: the 10-K prints it as 'Asset impairment and exit costs' and the 10-Q prints it as 'Exit costs'. One name is used here so the periods line up.
  • Total stockholders' equity is negative in every period shown. Altria's balance sheet reports a stockholders' equity deficit because the accumulated cost of repurchased stock (-$43.5 billion at June 30, 2026) exceeds earnings reinvested in the business. The figure stored as 'total_stockholders_equity' is the total including the $50 million noncontrolling interest, which is what the balance sheet balances against.
  • Earnings per share: Altria reports a single 'basic and diluted' figure, so basic and diluted EPS are identical. Under the two-class method the EPS numerator is earnings after removing the portion attributable to unvested share-based awards, which is slightly less than net earnings; both figures are carried, as 'earnings_for_basic_and_diluted_eps' and 'net_earnings'. Weighted-average shares come from the earnings per share note in each filing (Note 12 in the 10-K, Note 7 in the 10-Q).
  • Dividends declared per share are taken from the captions on the statements of stockholders' equity (deficit): $4.16, $4.00 and $3.84 for 2025, 2024 and 2023, and $1.06 and $1.02 for the second quarters of 2026 and 2025. Dividends paid on common stock in the cash flow block are the cash amounts, which differ from declared amounts because the fourth-quarter dividend is paid in January.
  • Shares outstanding at each period end are issued shares (2,805,961,317 in every period) less the shares carried at cost of repurchased stock, as disclosed on the balance sheet. The June 30, 2026 figure of 1,669,743,926 is the same count Altria prints on the 10-Q cover page.
  • Segment figures use Altria's own measure of segment profitability, operating companies income, which is operating income before general corporate expenses and amortization of intangibles. The reportable segments changed between the two filings: in the FY2025 10-K, e-vapor products met the quantitative threshold for separate presentation (because of the 2025 non-cash impairments) and Altria recast prior years to show it, so the annual segment tables here carry four lines. In the first quarter of 2026 Altria concluded e-vapor was no longer of continuing significance, removed it as a reportable segment, and folded it back into the all other category for all periods presented, so the quarterly and six-month segment tables here carry three. Annual and quarterly segment lines are consequently not directly comparable for e-vapor and all other; smokeable products and oral tobacco products are unaffected.
  • The quarterly entries carry no cash flow figures. The 10-Q presents cash flows only for the six months ended June 30, 2026 and 2025, and Altria's first-quarter 2026 earnings release contains no cash flow statement, so there is no published three-month operating cash flow or capital expenditure figure to report. The six-month cash flows appear in 'year_to_date' and 'prior_year_to_date'.
  • The trailing-twelve-months block covers July 1, 2025 through June 30, 2026 and is derived, not filed: the year ended December 31, 2025 plus the six months ended June 30, 2026 less the six months ended June 30, 2025, applied line by line to the income statement and the cash flow statement. Its diluted EPS ($4.75) and weighted-average share count (1,668 million) are derived the same way and are approximations of a true twelve-month weighted average.
  • Free cash flow is operating cash flow less capital expenditures, with capital expenditures carried with the negative sign the cash flow statement prints.
  • Total debt is the current portion of long-term debt plus long-term debt. Altria had no short-term borrowings outstanding at any of these period ends; the 10-K states that all long-term debt outstanding at December 31, 2025 and 2024 was fixed-rate, at a weighted-average coupon of approximately 4.5% and 4.3% respectively.

Uncertainties

  • No three-month cash flow statement exists for either quarter shown. Quarterly operating cash flow, capital expenditures and free cash flow are therefore absent rather than estimated.
  • No balance sheet is published here for the quarter ended June 30, 2025. The 10-Q's balance sheet columns are June 30, 2026 and December 31, 2025 only. The statement of stockholders' equity does show total stockholders' equity (deficit) of -$3,206 million at June 30, 2025, but a single line is not a balance sheet and it is not carried as one.
  • No balance sheet is published here for fiscal 2023. The FY2025 10-K's balance sheets cover December 31, 2025 and 2024 only.
  • Trailing-twelve-months diluted EPS and the trailing-twelve-months weighted-average share count are arithmetic combinations of reported periods, not reported figures. Because weighted-average share counts cannot be added and subtracted exactly, treat both as approximate; trailing net earnings divided by the derived share count gives $4.78 against the $4.75 obtained by combining the reported per-share amounts.
  • Altria's investments in equity securities are accounted for under the equity method, and the 10-K states that the audited financial statements of Anheuser-Busch InBev for the year ended December 31, 2025 will be filed by amendment within six months under Regulation S-X Rule 3-09. The equity-investment amounts carried here are as reported in the 10-K itself.
  • The segment presentation changed between the two filings (e-vapor products was a reportable segment in the FY2025 10-K and is back inside 'all other' in the Q2 2026 10-Q). The annual and quarterly segment tables here each follow the filing they came from and have not been conformed to one another.

Company details

NameAltria Group, Inc.
TickerMO
CIK0000764180
ExchangeNYSE
StateVirginia
IncorporationVirginia
SIC2111
OfficeManufacturing
IndustryCigarettes

Fiscal period

Fiscal year2026
Fiscal periodQ2
TagFY26Q2
Period end2026-06-30
Form10-Q
Accession0000764180-26-000094
Fiscal year end1231
Sourcefacts

Source filings

RoleCurrentFormFiscal yearFiscal periodTagPeriod endFiledAccessionSource
annualno10-K2025FYFY252025-12-312026-02-250000764180-26-000017reported
quarterlyyes10-Q2026Q2FY26Q22026-06-302026-07-300000764180-26-000094facts

Related companies

See every covered company and its filings data.

Not investment advice, see the Disclaimer.